Molecular mechanism and function of CD40/CD40L engagement in the immune system

Immunological Reviews

Volumn 229, Issue 1, 2009, Pages 152-172

  Elgueta, Raul ^a   Benson, Micah J ^a   De Vries, Victor C ^a   Wasiuk, Anna ^a   Guo, Yanxia ^a   Noelle, Randolph J ^a  

^a NORRIS COTTON CANCER CENTER   (United States)

Author keywords

CD40; CD40L; Cellular immunity; Graft tolerance; Humoral immunity; TRAF proteins; Tumor immunity; Tumor necrosis family

Indexed keywords

ABATACEPT; ANTINEOPLASTIC AGENT; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CP 870893; CYCLOSPORIN A; HCD 122; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G ANTIBODY; RAPAMYCIN; SGN 40; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADVANCED CANCER; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CELL FATE; CELLULAR IMMUNITY; CHILL; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG FEVER; DRUG TOLERABILITY; FLU LIKE SYNDROME; GRAFT REJECTION; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; LARGE CELL LYMPHOMA; LEUKEMIA; LIVER TOXICITY; MONOTHERAPY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RIGOR; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THYMUS; TRANSPLANTATION TOLERANCE; TUMOR CELL; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD40; B-LYMPHOCYTES; CD40 LIGAND; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PEPTIDES AND PROTEINS;

EID: 65349149089     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2009.00782.x     Document Type: Review

References (230)

1. Bretscher PA. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci USA 1999 96 : 185 190.
2. Quezada SA, et al. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004 22 : 307 328.
3. Bromley SK, et al. The immunological synapse and CD28-CD80 interactions. Nat Immunol 2001 2 : 1159 1166.
4. Au PY, Yeh WC. Physiological roles and mechanisms of signaling by TRAF2 and TRAF5. Adv Exp Med Biol 2007 597 : 32 47.
5. Linsley PS, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T-cell activation molecule. Science 1992 257 : 792 795.
6. van Kooten C, et al. CD40-CD40 ligand. J Leukoc Biol 2000 67 : 2 17.
7. Banchereau J, et al. Functional CD40 antigen on B cells, dendritic cells and fibroblasts. Adv Exp Med Biol 1995 378 : 79 83.
8. + T cell memory. Science 2002 297 : 2060 2063.
9. van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol 1997 9 : 330 337.
10. Graf D, Muller S, Korthauer U, van Kooten C, Weise C, Kroczek RA. A soluble form of TRAP (CD40 ligand) is rapidly released after T-cell activation. Eur J Immunol 1995 25 : 1749 1754.
11. Mazzei GJ, et al. Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem 1995 270 : 7025 7028.
12. Karpusas M, et al. 2 A crystal structure of an extracellular fragment of human CD40 ligand. Structure 1995 3 : 1031 1039.
13. Carbone E, et al. A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction. J Environ Monit 1997 185 : 2053 2060.
14. Danese S, Sans M, Fiocchi C. The CD40/CD40L costimulatory pathway in inflammatory bowel disease. Gut 2004 53 : 1035 1043.
15. Bishop GA, Moore CR, Xie P, Stunz LL, Kraus ZJ. TRAF proteins in CD40 signaling. Adv Exp Med Biol 2007 597 : 131 151.
16. Saemann MD, et al. Prevention of CD40-triggered dendritic cell maturation and induction of T-cell hyporeactivity by targeting of Janus kinase 3. Am J Transplant 2003 3 : 1341 1349.
17. Saemann MD, Kelemen P, Zeyda M, Bohmig G, Staffler G, Zlabinger GJ. CD40 triggered human monocyte-derived dendritic cells convert to tolerogenic dendritic cells when Jak3 activity is inhibited. Transplant Proc 2002 34 : 1407 1408.
18. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004 25 : 280 288.
19. Pullen SS, et al. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Biochemistry 1999 38 : 10168 10177.
20. Pullen SS, Miller HG, Everdeen DS, Dang TT, Crute JJ, Kehry MR. CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization. Biochemistry 1998 37 : 11836 11845.
21. Davies CC, Mak TW, Young LS, Eliopoulos AG. TRAF6 is required for TRAF2-dependent CD40 signal transduction in nonhemopoietic cells. Mol Cell Biol 2005 25 : 9806 9819.
22. Manning E, Pullen SS, Souza DJ, Kehry M, Noelle RJ. Cellular responses to murine CD40 in a mouse B cell line may be TRAF dependent or independent. Eur J Immunol 2002 32 : 39 49.
23. Lu LF, Cook WJ, Lin LL, Noelle RJ. CD40 signaling through a newly identified tumor necrosis factor receptor-associated factor 2 (TRAF2) binding site. J Biol Chem 2003 278 : 45414 45418.
24. Lu LF, et al. The in vivo function of a noncanonical TRAF2-binding domain in the C-terminus of CD40 in driving B-cell growth and differentiation. Blood 2007 110 : 193 200.
25. McWhirter SM, Pullen SS, Holton JM, Crute JJ, Kehry MR, Alber T. Crystallographic analysis of CD40 recognition and signaling by human TRAF2. Proc Natl Acad Sci USA 1999 96 : 8408 8413.
26. Haswell LE, Glennie MJ, Al-Shamkhani A. Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur J Immunol 2001 31 : 3094 3100.
27. Pullen SS, Dang TT, Crute JJ, Kehry MR. CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs). Binding site specificity and activation of downstream pathways by distinct TRAFs. J Biol Chem 1999 274 : 14246 14254.
28. Barr TA, Heath AW. Functional activity of CD40 antibodies correlates to the position of binding relative to CD154. Immunology 2001 102 : 39 43.
29. Schwenzer R, et al. The human tumor necrosis factor (TNF) receptor-associated factor 1 gene (TRAF1) is up-regulated by cytokines of the TNF ligand family and modulates TNF-induced activation of NF-kappaB and c-Jun N-terminal kinase. J Biol Chem 1999 274 : 19368 19374.
30. Zapata JM, et al. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol 2000 165 : 5084 5096.
31. Arron JR, Pewzner-Jung Y, Walsh MC, Kobayashi T, Choi Y. Regulation of the subcellular localization of tumor necrosis factor receptor-associated factor (TRAF)2 by TRAF1 reveals mechanisms of TRAF2 signaling. J Exp Med 2002 196 : 923 934.
32. Xie P, Hostager BS, Munroe ME, Moore CR, Bishop GA. Cooperation between TNF receptor-associated factors 1 and 2 in CD40 signaling. J Immunol 2006 176 : 5388 5400.
33. Hostager BS, Haxhinasto SA, Rowland SL, Bishop GA. Tumor necrosis factor receptor-associated factor 2 (TRAF2)-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling. J Biol Chem 2003 278 : 45382 45390.
34. Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzweig MC, Choi Y. TRAF2 is essential for Jnk but not NF-kappaB activation and regulates lymphocyte proliferation and survival. Immunity 1997 7 : 703 713.
35. Yeh WC, et al. Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 1997 7 : 715 725.
36. Gallagher E, et al. Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production. Nat Immunol 2007 8 : 57 63.
37. Vince JE, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007 131 : 682 693.
38. Gardam S, Sierro F, Basten A, Mackay F, Brink R. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 2008 28 : 391 401.
39. Vallabhapurapu S, et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol 2008 9 : 1364 1370.
40. Zarnegar BJ, et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 2008 9 : 1371 1378.
41. Brown KD, Hostager BS, Bishop GA. Regulation of TRAF2 signaling by self-induced degradation. J Biol Chem 2002 277 : 19433 19438.
42. He JQ, Oganesyan G, Saha SK, Zarnegar B, Cheng G. TRAF3 and its biological function. Adv Exp Med Biol 2007 597 : 48 59.
43. Xie P, Hostager BS, Bishop GA. Requirement for TRAF3 in signaling by LMP1 but not CD40 in B lymphocytes. J Exp Med 2004 199 : 661 671.
44. Propst SM, Estell K, Schwiebert LM. CD40-mediated activation of NF-kappa B in airway epithelial cells. J Biol Chem 2002 277 : 37054 37063.
45. Urbich C, Mallat Z, Tedgui A, Clauss M, Zeiher AM, Dimmeler S. Upregulation of TRAF-3 by shear stress blocks CD40-mediated endothelial activation. J Clin Invest 2001 108 : 1451 1458.
46. Hauer J, et al. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci USA 2005 102 : 2874 2879.
47. Nakano H, et al. Targeted disruption of Traf5 gene causes defects in CD40- and CD27-mediated lymphocyte activation. Proc Natl Acad Sci USA 1999 96 : 9803 9808.
48. Rowland SL, Tremblay MM, Ellison JM, Stunz LL, Bishop GA, Hostager BS. A novel mechanism for TNFR-associated factor 6-dependent CD40 signaling. J Immunol 2007 179 : 4645 4653.
49. Arron JR, et al. A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine (trance) and CD40L-mediated Akt activation. J Biol Chem 2001 276 : 30011 30017.
50. Davies CC, Mason J, Wakelam MJ, Young LS, Eliopoulos AG. Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells. J Biol Chem 2004 279 : 1010 1019.
51. + T cell memory responses. J Immunol 2004 172 : 6047 6056.
52. Cardone MH, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998 282 : 1318 1321.
53. Datta SR, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997 91 : 231 241.
54. Qiao G, et al. Negative regulation of CD40-mediated B cell responses by E3 ubiquitin ligase Casitas-B-lineage lymphoma protein-B. J Immunol 2007 179 : 4473 4479.
55. Hanissian SH, Geha RS. Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. Immunity 1997 6 : 379 387.
56. Revy P, et al. Activation of the Janus kinase 3-STAT5a pathway after CD40 triggering of human monocytes but not of resting B cells. J Immunol 1999 163 : 787 793.
57. Pine R, Canova A, Schindler C. Tyrosine phosphorylated p91 binds to a single element in the ISGF2/IRF-1 promoter to mediate induction by IFN alpha and IFN gamma, and is likely to autoregulate the p91 gene. EMBO J 1994 13 : 158 167.
58. Banchereau J, et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994 12 : 881 922.
59. Barrett TB, Shu G, Clark EA. CD40 signaling activates CD11a/CD18 (LFA-1)-mediated adhesion in B cells. J Immunol 1991 146 : 1722 1729.
60. Clark EA, Ledbetter JA. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc Natl Acad Sci USA 1986 83 : 4494 4498.
61. Jabara HH, Fu SM, Geha RS, Vercelli D. CD40 and IgE: synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells. J Exp Med 1990 172 : 1861 1864.
62. Foy TM, Durie FH, Noelle RJ. The expansive role of CD40 and its ligand, gp39, in immunity. Semin Immunol 1994 6 : 259 266.
63. Foy TM, Laman JD, Ledbetter JA, Aruffo A, Claassen E, Noelle RJ. gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J Exp Med 1994 180 : 157 163.
64. Foy TM, Shepherd DM, Durie FH, Aruffo A, Ledbetter JA, Noelle RJ. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J Exp Med 1993 178 : 1567 1575.
65. Mitchison NA. T-cell-B-cell cooperation. Nat Rev Immunol 2004 4 : 308 312.
66. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 1985 314 : 537 539.
67. Rock KL, Benacerraf B, Abbas AK. Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors. J Exp Med 1984 160 : 1102 1113.
68. Loughnan MS, Nossal GJ. Interleukins 4 and 5 control expression of IL-2 receptor on murine B cells through independent induction of its two chains. Nature 1989 340 : 76 79.
69. Loughnan MS, Takatsu K, Harada N, Nossal GJ. T-cell-replacing factor (interleukin 5) induces expression of interleukin 2 receptors on murine splenic B cells. Proc Natl Acad Sci USA 1987 84 : 5399 5403.
70. Noelle R, Krammer PH, Ohara J, Uhr JW, Vitetta ES. Increased expression of Ia antigens on resting B cells: an additional role for B-cell growth factor. Proc Natl Acad Sci USA 1984 81 : 6149 6153.
71. Oliver K, Noelle RJ, Uhr JW, Krammer PH, Vitetta ES. B-cell growth factor (B-cell growth factor I or B-cell-stimulating factor, provisional 1) is a differentiation factor for resting B cells and may not induce cell growth. Proc Natl Acad Sci USA 1985 82 : 2465 2467.
72. Bartlett WC, Michael A, McCann J, Yuan D, Claassen E, Noelle RJ. Cognate interactions between helper T cells and B cells. II. Dissection of cognate help by using a class II-restricted, antigen-specific, IL-2-dependent helper T cell clone. J Immunol 1989 143 : 1745 1754.
73. Bartlett WC, McCann J, Shepherd DM, Roy M, Noelle RJ. Cognate interactions between helper T cells and B cells. IV. Requirements for the expression of effector phase activity by helper T cells. J Immunol 1990 145 : 3956 3962.
74. Brian AA. Stimulation of B-cell proliferation by membrane-associated molecules from activated T cells. Proc Natl Acad Sci USA 1988 85 : 564 568.
75. Hodgkin PD, Yamashita LC, Coffman RL, Kehry MR. Separation of events mediating B cell proliferation and Ig production by using T cell membranes and lymphokines. J Immunol 1990 145 : 2025 2034.
76. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci USA 1992 89 : 6550 6554.
77. Armitage RJ, et al. Molecular and biological characterization of a murine ligand for CD40. Nature 1992 357 : 80 82.
78. Bergtold A, Desai DD, Gavhane A, Clynes R. Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. Immunity 2005 23 : 503 514.
79. Pape KA, Catron DM, Itano AA, Jenkins MK. The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. Immunity 2007 26 : 491 502.
80. Wykes M, Pombo A, Jenkins C, MacPherson GG. Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J Immunol 1998 161 : 1313 1319.
81. Jacob J, Kassir R, Kelsoe G. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. I. The architecture and dynamics of responding cell populations. J Exp Med 1991 173 : 1165 1175.
82. Jacob J, Kelsoe G. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. II. A common clonal origin for periarteriolar lymphoid sheath-associated foci and germinal centers. J Exp Med 1992 176 : 679 687.
83. MacLennan IC. Germinal centers. Annu Rev Immunol 1994 12 : 117 139.
84. Van den Eertwegh AJ, et al. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions. J Exp Med 1993 178 : 1555 1565.
85. Garside P, Ingulli E, Merica RR, Johnson JG, Noelle RJ, Jenkins MK. Visualization of specific B and T lymphocyte interactions in the lymph node. Science 1998 281 : 96 99.
86. Xu J, et al. Mice deficient for the CD40 ligand. Immunity 1994 1 : 423 431.
87. Benson MJ, Erickson LD, Gleeson MW, Noelle RJ. Affinity of antigen encounter and other early B-cell signals determine B-cell fate. Curr Opin Immunol 2007 19 : 275 280.
88. O'Connor BP, et al. Imprinting the fate of antigen-reactive B cells through the affinity of the B cell receptor. J Immunol 2006 177 : 7723 7732.
89. Paus D, Phan TG, Chan TD, Gardam S, Basten A, Brink R. Antigen recognition strength regulates the choice between extrafollicular plasma cell and germinal center B cell differentiation. J Exp Med 2006 203 : 1081 1091.
90. Phan TG, et al. High affinity germinal center B cells are actively selected into the plasma cell compartment. J Exp Med 2006 203 : 2419 2424.
91. Erickson LD, et al. Short-circuiting long-lived humoral immunity by the heightened engagement of CD40. J Clin Invest 2002 109 : 613 620.
92. Breitfeld D, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B-cell follicles, and support immunoglobulin production. J Exp Med 2000 192 : 1545 1552.
93. King C, Tangye SG, Mackay CR. T follicular helper (TFH) cells in normal and dysregulated immune responses. Annu Rev Immunol 2008 26 : 741 766.
94. Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med 2000 192 : 1553 1562.
95. Ansel KM, McHeyzer-Williams LJ, Ngo VN, McHeyzer-Williams MG, Cyster JG. In vivo-activated CD4 T cells upregulate CXC chemokine receptor 5 and reprogram their response to lymphoid chemokines. J Exp Med 1999 190 : 1123 1134.
96. Ansel KM, et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000 406 : 309 314.
97. Bowman EP, et al. Developmental switches in chemokine response profiles during B cell differentiation and maturation. J Exp Med 2000 191 : 1303 1318.
98. Forster R, Mattis AE, Kremmer E, Wolf E, Brem G, Lipp M. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 1996 87 : 1037 1047.
99. Gunn MD, Ngo VN, Ansel KM, Ekland EH, Cyster JG, Williams LT. A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature 1998 391 : 799 803.
100. Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M, Moser B. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 1998 187 : 655 660.
101. Rogerson B, Hackett J Jr., Peters A, Haasch D, Storb U. Mutation pattern of immunoglobulin transgenes is compatible with a model of somatic hypermutation in which targeting of the mutator is linked to the direction of DNA replication. EMBO J 1991 10 : 4331 4341.
102. Allen CD, et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol 2004 5 : 943 952.
103. Allen CD, Okada T, Tang HL, Cyster JG. Imaging of germinal center selection events during affinity maturation. Science 2007 315 : 528 531.
104. Liu YJ, et al. Follicular dendritic cells specifically express the long CR2/CD21 isoform. J Exp Med 1997 185 : 165 170.
105. Hannum LG, Haberman AM, Anderson SM, Shlomchik MJ. Germinal center initiation, variable gene region hypermutation, and mutant B cell selection without detectable immune complexes on follicular dendritic cells. J Exp Med 2000 192 : 931 942.
106. Casamayor-Palleja M, Feuillard J, Ball J, Drew M, MacLennan IC. Centrocytes rapidly adopt a memory B cell phenotype on co-culture with autologous germinal centre T cell-enriched preparations. Int Immunol 1996 8 : 737 744.
107. Holder MJ, et al. Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bc1-2 induction. Eur J Immunol 1993 23 : 2368 2371.
108. Liu YJ, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan IC. Mechanism of antigen-driven selection in germinal centres. Nature 1989 342 : 929 931.
109. Hennino A, Berard M, Krammer PH, Defrance T. FLICE-inhibitory protein is a key regulator of germinal center B cell apoptosis. J Exp Med 2001 193 : 447 458.
110. Tuscano JM, Druey KM, Riva A, Pena J, Thompson CB, Kehrl JH. Bcl-x rather than Bcl-2 mediates CD40-dependent centrocyte survival in the germinal center. Blood 1996 88 : 1359 1364.
111. Takahashi Y, Dutta PR, Cerasoli DM, Kelsoe G. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. V. Affinity maturation develops in two stages of clonal selection. J Exp Med 1998 187 : 885 895.
112. Ahonen C, et al. The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells. Nat Immunol 2002 3 : 451 456.
113. Jabara H, et al. The binding site for TRAF2 and TRAF3 but not for TRAF6 is essential for CD40-mediated immunoglobulin class switching. Immunity 2002 17 : 265 276.
114. Yasui T, et al. Dissection of B cell differentiation during primary immune responses in mice with altered CD40 signals. Int Immunol 2002 14 : 319 329.
115. Cheng G, Cleary AM, Ye ZS, Hong DI, Lederman S, Baltimore D. Involvement of CRAF1, a relative of TRAF, in CD40 signaling. Science 1995 267 : 1494 1498.
116. Lee HH, Dempsey PW, Parks TP, Zhu X, Baltimore D, Cheng G. Specificities of CD40 signaling: involvement of TRAF2 in CD40-induced NF-kappaB activation and intercellular adhesion molecule-1 up-regulation. Proc Natl Acad Sci USA 1999 96 : 1421 1426.
117. Ochs HD, Hollenbaugh D, Aruffo A. The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency. Semin Immunol 1994 6 : 337 341.
118. D'Orlando O, et al. Outside inside signalling in CD40-mediated B-cell activation. J Biol Regul Homeost Agents 2007 21 : 49 62.
119. Agarwal A, Newell KA. The role of positive costimulatory molecules in transplantation and tolerance. Curr Opin Organ Transplant 2008 13 : 366 372.
120. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 2007 13 : 1083 1088.
121. Toubi E, Shoenfeld Y. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity 2004 37 : 457 464.
122. Lenschow DJ, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA-4lg. Science 1992 257 : 789 792.
123. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994 1 : 793 801.
124. Baliga P, et al. CTLA-4Ig prolongs allograft survival while suppressing cell-mediated immunity. Transplantation 1994 58 : 1082 1090.
125. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993 177 : 925 935.
126. Ranheim EA, Kipps TJ. Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell Immunol 1995 161 : 226 235.
127. + T cells can trigger allograft rejection. J Immunol 2000 165 : 1111 1118.
128. Lehnert AM, et al. Blockade of the CD28 and CD40 pathways result in the acceptance of pig and rat islet xenografts but not rat cardiac grafts in mice. Transpl Immunol 2001 9 : 51 56.
129. + T cell tolerance and linked suppression. J Immunol 1999 163 : 4805 4810.
130. Li Y, Zheng XX, Li XC, Zand MS, Strom TB. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 1998 66 : 1387 1388.
131. Kang HG, Zhang D, Degauque N, Mariat C, Alexopoulos S, Zheng XX. Effects of cyclosporine on transplant tolerance: the role of IL-2. Am J Transplant 2007 7 : 1907 1916.
132. Chalermskulrat W, et al. Combined donor specific transfusion and anti-CD154 therapy achieves airway allograft tolerance. Thorax 2006 61 : 61 67.
133. Larsen CP, et al. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 1996 61 : 4 9.
134. Parker DC, et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA 1995 92 : 9560 9564.
135. Quezada SA, et al. Mechanisms of donor-specific transfusion tolerance: preemptive induction of clonal T-cell exhaustion via indirect presentation. Blood 2003 102 : 1920 1926.
136. Wood ML, Gottschalk R, Monaco AP. Comparison of immune responsiveness in mice after single or multiple donor-specific transfusions. J Immunol 1984 132 : 651 655.
137. Zheng XX, et al. Blockade of CD40L/CD40 costimulatory pathway in a DST presensitization model of islet allograft leads to a state of Allo-Ag specific tolerance and permits subsequent engraftment of donor strain islet or heart allografts. Transplant Proc 1999 31 : 627 628.
138. + regulatory T cells contributes to skin transplant tolerance. Transplantation 2003 76 : 1375 1379.
139. Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, Steinman RM. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 2002 196 : 1091 1097.
140. Coulombe M, Yang H, Wolf LA, Gill RG. Tolerance to antigen-presenting cell-depleted islet allografts is CD4 T cell dependent. J Immunol 1999 162 : 2503 2510.
141. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998 392 : 245 252.
142. Frleta D, et al. Distinctive maturation of in vitro versus in vivo anti-CD40 mAb-matured dendritic cells in mice. J Immunother 2003 26 : 72 84.
143. Ouaaz F, Arron J, Zheng Y, Choi Y, Beg AA. Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity 2002 16 : 257 270.
144. Wong BR, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997 186 : 2075 2080.
145. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999 5 : 1298 1302.
146. Wekerle T, et al. Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death. J Immunol 2001 166 : 2311 2316.
147. Wells AD, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999 5 : 1303 1307.
148. Graca L, Le Moine A, Cobbold SP, Waldmann H. Antibody-induced transplantation tolerance: the role of dominant regulation. Immunol Res 2003 28 : 181 191.
149. + cell subsets and different mechanisms. Transplantation 2004 78 : 660 667.
150. Guillonneau C, et al. Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients. J Immunol 2007 179 : 8164 8171.
151. Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 2007 204 : 1765 1774.
152. + regulatory T cells. Proc Natl Acad Sci USA 2008 105 : 9331 9336.
153. Markees TG, et al. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA-4. J Clin Invest 1998 101 : 2446 2455.
154. Vincenti F. Costimulation blockade in autoimmunity and transplantation. J Allergy Clin Immunol 2008 121 : 299 306 quiz 7-8.
155. Mai G, del Rio ML, Tian J, Ramirez P, Buhler L, Rodriguez-Barbosa JI. Blockade of the PD-1/PD-1L pathway reverses the protective effect of anti-CD40L therapy in a rat to mouse concordant islet xenotransplantation model. Xenotransplantation 2007 14 : 243 248.
156. Schilbach K, et al. PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating T cells during murine GVHD across minor histocompatibility antigen barriers. Transplantation 2007 84 : 214 222.
157. Vu MD, Clarkson MR, Yagita H, Turka LA, Sayegh MH, Li XC. Critical, but conditional, role of OX40 in memory T cell-mediated rejection. J Immunol 2006 176 : 1394 1401.
158. Berney T, et al. The effect of simultaneous CD154 and LFA-1 blockade on the survival of allogeneic islet grafts in nonobese diabetic mice. Transplantation 2003 76 : 1669 1674.
159. Kobayashi T, Harb G, Rayat GR. Prolonged survival of microencapsulated neonatal porcine islets in mice treated with a combination of anti-CD154 and anti-LFA-1 monoclonal antibodies. Transplantation 2005 80 : 821 827.
160. + T cells. J Immunol 2005 175 : 7855 7866.
161. Nicolls MR, Coulombe M, Beilke J, Gelhaus HC, Gill RG. CD4-dependent generation of dominant transplantation tolerance induced by simultaneous perturbation of CD154 and LFA-1 pathways. J Immunol 2002 169 : 4831 4839.
162. Rayat GR, Gill RG. Indefinite survival of neonatal porcine islet xenografts by simultaneous targeting of LFA-1 and CD154 or CD45RB. Diabetes 2005 54 : 443 451.
163. Wang Y, Gao D, Lunsford KE, Frankel WL, Bumgardner GL. Targeting LFA-1 synergizes with CD40/CD40L blockade for suppression of both CD4-dependent and CD8-dependent rejection. Am J Transplant 2003 3 : 1251 1258.
164. Lee JH, Ha J, Kim SH, Kim SJ. IL-2 pathway blocking in combination with anti-CD154 synergistically establishes mixed macrochimerism with limited dose of bone marrow cells and prolongs skin graft survival in mice. J Korean Med Sci 2006 21 : 1005 1011.
165. Pan H, et al. Anti-CD25 mAb, anti-IL2 mAb, and IL2 block tolerance induction through anti-CD154 mAb and rapamycin in xenogeneic islet transplantation. Transplant Proc 2007 39 : 3452 3454.
166. Wang Y, Dai H, Liu Z, Cheng X, Tellides G, Dai Z. Neutralizing IL-7 promotes long-term allograft survival induced by CD40/CD40L costimulatory blockade. Am J Transplant 2006 6 : 2851 2860.
167. Demirci G, Strom TB, Li XC. Islet allograft rejection in nonobese diabetic mice involves the common gamma-chain and CD28/CD154-dependent and -independent mechanisms. J Immunol 2003 171 : 3878 3885.
168. Li XC, Strom TB. A rare find - cells that improve bone marrow transplantation. Nat Med 2000 6 : 866 867.
169. Trambley J, et al. Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection. J Clin Invest 1999 104 : 1715 1722.
170. Williams MA, et al. Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts. J Immunol 2000 165 : 6849 6857.
171. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005 6 : 338 344.
172. Grohmann U, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002 3 : 1097 1101.
173. Demirci G, et al. Critical role of OX40 in CD28 and CD154-independent rejection. J Immunol 2004 172 : 1691 1698.
174. + Tregs. Blood 2007 110 : 2501 2510.
175. + Tregs. Transplantation 2008 85 : 1659 1662.
176. Habicht A, Najafian N, Yagita H, Sayegh MH, Clarkson MR. New insights in CD28-independent allograft rejection. Am J Transplant 2007 7 : 1917 1926.
177. Baxendale AJ, et al. Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth. Oncogene 2005 24 : 7913 7923.
178. Bedian V, et al. In vitro characterization and pre-clinical pharmacokinetics of CP-870,893, a human anti-CD40 agonist antibody. J Clin Oncol 2006 24 : 2539. (Abstract).
179. Bensinger W, et al. A phase 1 dose escalation study of a fully human, antagonist anti-CD40 antibody, HCD 122 (formerly CHIR-12.12), in patients with relapsed and refractory multiple myeloma. Blood 2006 108 : 3590. (Abstract).
180. + T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med 2007 13 : 354 360.
181. Byrd JC, et al. Pharmacokinetics and pharmacodynamics from a first-in-human phase 1 dose escalation study with antagonist anti-CD40 antibody, HCD 122 (formerly CHIR-12.12) in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2006 108 : 2837. (Abstract).
182. Tan J, et al. CD40 is expressed and functional on neuronal cells. EMBO J 2002 21 : 643 652.
183. Young LS, Dawson CW, Brown KW, Rickinson AB. Identification of a human epithelial cell surface protein sharing an epitope with the C3d/Epstein-Barr virus receptor molecule of B lymphocytes. Int J Cancer 1989 43 : 786 794.
184. Cooke PW, James ND, Ganesan R, Wallace M, Burton A, Young LS. CD40 expression in bladder cancer. J Pathol 1999 188 : 38 43.
185. Altenburg A, Baldus SE, Smola H, Pfister H, Hess S. CD40 ligand-CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN-gamma. J Immunol 1999 162 : 4140 4147.
186. Gallagher NJ, Eliopoulos AG, Agathangelo A, Oates J, Crocker J, Young LS. CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion. Mol Pathol 2002 55 : 110 120.
187. Agathanggelou A, Niedobitek G, Chen R, Nicholls J, Yin W, Young LS. Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. Am J Pathol 1995 147 : 1152 1160.
188. Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998 101 : 1133 1141.
189. Pellat-Deceunynck C, Amiot M, Robillard N, Wijdenes J, Bataille R. CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. Cancer Res 1996 56 : 1909 1916.
190. Teoh G, et al. CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Blood 2000 95 : 1039 1046.
191. Aldinucci D, et al. CD40L induces proliferation, self-renewal, rescue from apoptosis, and production of cytokines by CD40-expressing AML blasts. Exp Hematol 2002 30 : 1283 1292.
192. Choi MS, Boise LH, Gottschalk AR, Quintans J, Thompson CB, Klaus GG. The role of Bcl-XL in CD40-mediated rescue from anti-mu-induced apoptosis in WEHI-231 B lymphoma cells. Eur J Immunol 1995 25 : 1352 1357.
193. Sarma V, et al. Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis. J Biol Chem 1995 270 : 12343 12346.
194. Zhang X, et al. Up-regulation of Bcl-xL expression protects CD40-activated human B cells from Fas-mediated apoptosis. Cell Immunol 1996 173 : 149 154.
195. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA 1999 96 : 9136 9141.
196. Pham LV, et al. A CD40 Signalosome anchored in lipid rafts leads to constitutive activation of NF-kappaB and autonomous cell growth in B cell lymphomas. Immunity 2002 16 : 37 50.
197. Challa A, et al. Population depletion activates autonomous CD154-dependent survival in biopsylike Burkitt lymphoma cells. Blood 2002 99 : 3411 3418.
198. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000 164 : 2200 2206.
199. Funakoshi S, et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994 83 : 2787 2794.
200. Wingett DG, Vestal RE, Forcier K, Hadjokas N, Nielson CP. CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res Treat 1998 50 : 27 36.
201. Eliopoulos AG, et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 2000 20 : 5503 5515.
202. Hess S, Engelmann H. A novel function of CD40: induction of cell death in transformed cells. J Environ Monit 1996 183 : 159 167.
203. Eliopoulos AG, et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 1996 13 : 2243 2254.
204. Hirano A, et al. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 1991 93 : 2999 3007.
205. Tong AW, et al. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 2001 7 : 691 703.
206. Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 2003 10 : 1 13.
207. Mackey MF, et al. Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res 1997 57 : 2569 2574.
208. French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999 5 : 548 553.
209. Diehl L, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999 5 : 774 779.
210. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999 5 : 780 787.
211. van Mierlo GJ, et al. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA 2002 99 : 5561 5566.
212. Kedl RM, Jordan M, Potter T, Kappler J, Marrack P, Dow S. CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination. Proc Natl Acad Sci USA 2001 98 : 10811 10816.
213. Ahonen CL, et al. Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood 2008 111 : 3116 3125.
214. Grossmann ME, Brown MP, Brenner MK. Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther 1997 8 : 1935 1943.
215. Ribas A, et al. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells. Cancer Res 2001 61 : 8787 8793.
216. Kikuchi T, Crystal RG. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum Gene Ther 1999 10 : 1375 1387.
217. Kikuchi T, Moore MA, Crystal RG. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 2000 96 : 91 99.
218. Forero-Torres A, et al. A humanized antibody against CD40 (SGN-CD40) is well tolerated and active in non-Hodgkin's lymphoma (NHL): results of a phase 1 study. J Clin Oncol 2006 24 : 7534. (Abstract).
219. Vonderheide RH, et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 2001 19 : 3280 3287.
220. Younes A. CD40 ligand therapy of lymphoma patients. J Clin Oncol 2001 19 : 4351 4353.
221. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000 96 : 2917 2924.
222. Kipps TJ, Chu P, Wierda WG. Immunogenetic therapy for B-cell malignancies. Semin Oncol 2000 27 : 104 109.
223. Schultze JL, Anderson KC, Gilleece MH, Gribben JG, Nadler LM. A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2. Br J Haematol 2001 113 : 455 460.
224. Vonderheide RH, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007 25 : 876 883.
225. Hussein MA, et al. A phase I humanized anti-CD40 monoclonal antibody (SGN-40) in patients with multiple myeloma. Blood 2005 106 : 3576 (Abstract).
226. Rousseau RF, et al. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood 2006 107 : 1332 1341.
227. Alexandroff AB, et al. Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol Immunol 2000 37 : 515 526.
228. Luqman M, et al. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008 112 : 711 720.
229. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003 63 : 4490 4496.
230. Honeychurch J, Glennie MJ, Johnson PW, Illidge TM. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood 2003 102 : 1449 1457.